NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Biotrial

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biotrial to Exhibit At Two Major Life Science Conferences in February - Biotrial is pleased to announce that it will be exhibiting at the 20th AGAH (Association for Applied Human Pharmacology) Annual Meeting in Hamburg, Germany and at the 9th Annual Phase I Clinical Trials in London, UK - IIR-Events.com / Biotrial.com
Biotrial to Exhibit At Two Major Life Science Conferences in February

 

NewswireTODAY - /newswire/ - Rennes, Ille-et-Vilaine, France, 2010/02/08 - Biotrial is pleased to announce that it will be exhibiting at the 20th AGAH (Association for Applied Human Pharmacology) Annual Meeting in Hamburg, Germany and at the 9th Annual Phase I Clinical Trials in London, UK - IIR-Events.com / Biotrial.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

During the 20th AGAH Annual Meeting (agah.info) from February 21st–23rd, 2010, Biotrial will be exhibiting at Booth #10. This event will review past and present approaches to drug development, and will take a close look at special populations, difficult pharmacokinetic conditions and how to adapt to changing regulatory environments.

From February 23rd–24th, 2010 at the 11th Annual Phase I Clinical Trials (iir-events.com) Biotrial will be located at Booth #8. Alain Patat, VP Medical Scientific & Quality Affairs at Biotrial, said: “I am looking forward to attending this event, which focuses this year on assessing the significant advances in scientific and technological approaches for obtaining clinical data at earlier stages of drug development. This is a subject of interest for Biotrial who has been involved and committed for many years now to help the life science industry achieve great milestones in early compound development.”
Both of these events provide great platforms to share information and experiences and are an opportunity for Biotrial to meet with our present and future customers. We invite you to visit us at the booth locations indicated, or to contact one of our representatives to schedule an individual meeting: Matthew Koneth (matthew.konneh[.]biotrial.com) for the Phase I event in London, and Anna Lainé for the AGAH meeting in Germany.

About Biotrial

Founded in 1989 by Jean-Marc Gandon, PharmD, (President & CEO), Biotrial (biotrial.com) is an independent and privately owned CRO.
With 150 beds and a staff of 250 in several subsidiaries in France and the UK, Biotrial runs over 80 studies per year, either in their own clinics in Paris and Rennes, or in cooperation with hospital specialists and general practitioners.

With a large range of services from Phase I studies, Clinical Trial Management Phase II-IV, Oncology, Data Management, Biostatistics, Core Lab (ECG, MRI), Medical Writing, Non-Clinical Pharmacology, QA & advice in Regulatory Affairs, Biotrial can manage every step of your development process.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Biotrial

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biotrial to Exhibit At Two Major Life Science Conferences in February

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Anne Peron - Biotrial.com 
+33(0)2 99 59 91 91 anne.peron[.]biotrial.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biotrial securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biotrial / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)